{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:51:26Z","timestamp":1789044686480,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Manuka Bioscience Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-026-05274-w","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T02:05:39Z","timestamp":1770084339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomised controlled trial of m\u0101nuka oil-based ECMT-154\u2122 vs. vehicle control for the topical treatment of eczema, conducted in community pharmacies in New Zealand"],"prefix":"10.1186","volume":"26","author":[{"given":"Gabrielle","family":"Shortt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Shortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyley","family":"Kerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie","family":"Eathorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Biggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suki","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Semprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"5","key":"5274_CR1","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","volume":"113","author":"SGO Johansson","year":"2004","unstructured":"Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"10023","key":"5274_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"issue":"9","key":"5274_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00128071-200304090-00006","volume":"4","author":"J L\u00fcbbe","year":"2003","unstructured":"L\u00fcbbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641\u201354.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"5274_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5415\/apallergy.2013.3.3.161","volume":"3","author":"T Clayton","year":"2013","unstructured":"Clayton T, Asher MI, Crane J, Ellwood P, Mackay R, Mitchell EA, et al. Time trends, ethnicity and risk factors for eczema in new Zealand children: ISAAC phase three. Asia Pac Allergy. 2013;3(3):161\u201378.","journal-title":"Asia Pac Allergy"},{"issue":"6","key":"5274_CR5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","volume":"124","author":"JA Odhiambo","year":"2009","unstructured":"Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251\u2013e125823.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"5274_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000056219","volume":"70","author":"A Buske-Kirschbaum","year":"2001","unstructured":"Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom. 2001;70(1):6\u201316.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"5274_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1744666X.2016.1212660","volume":"13","author":"R Kantor","year":"2017","unstructured":"Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017;13(1):15\u201326.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"5274_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/jid.2008.259","volume":"129","author":"A De Benedetto","year":"2009","unstructured":"De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: A disease caused by innate immune defects? J Invest Dermatology. 2009;129(1):14\u201330.","journal-title":"J Invest Dermatology"},{"issue":"6","key":"5274_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","volume":"26","author":"JA Geoghegan","year":"2018","unstructured":"Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship. Trends Microbiol. 2018;26(6):484\u201397.","journal-title":"Trends Microbiol"},{"issue":"8","key":"5274_CR10","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/jid.2009.133","volume":"129","author":"MJ Cork","year":"2009","unstructured":"Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatology. 2009;129(8):1892\u2013908.","journal-title":"J Invest Dermatology"},{"issue":"2","key":"5274_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2332\/allergolint.13-RAI-0564","volume":"62","author":"DYM Leung","year":"2013","unstructured":"Leung DYM. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergology Int. 2013;62(2):151\u201361.","journal-title":"Allergology Int"},{"issue":"11","key":"5274_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archderm.1992.01680210087014","volume":"128","author":"JD Bos","year":"1992","unstructured":"Bos JD, Wierenga EA, Sillevis Smitt JH, van der Heijden FL, Kapsenberg ML. Immune dysregulation in atopic eczema. Arch Dermatol. 1992;128(11):1509\u201312.","journal-title":"Arch Dermatol"},{"issue":"6","key":"5274_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, et al. Progressive activation of Th2\/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"5274_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"5274_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1185\/03007990903512156","volume":"26","author":"EL Simpson","year":"2010","unstructured":"Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633\u201340.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"5274_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12016-015-8486-7","volume":"51","author":"M Chong","year":"2016","unstructured":"Chong M, Fonacier L. Treatment of eczema: corticosteroids and beyond. Clin Rev Allergy Immunol. 2016;51(3):249\u201362.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"5274_CR17","first-page":"181","volume":"8","author":"JH Lee","year":"2016","unstructured":"Lee JH, Son SW, Cho SH. Compr Rev Treat Atopic Eczema. 2016;8(3):181\u201390.","journal-title":"Compr Rev Treat Atopic Eczema"},{"issue":"4","key":"5274_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2011.10449.x","volume":"165","author":"H Aubert-Wastiaux","year":"2011","unstructured":"Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808\u201314.","journal-title":"Br J Dermatol"},{"issue":"11","key":"5274_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/ph13110343","volume":"13","author":"C Mathew","year":"2020","unstructured":"Mathew C, Tesfaye W, Rasmussen P, Peterson GM, Bartholomaeus A, Sharma M, et al. M\u0101nuka Oil\u2014A review of antimicrobial and other medicinal properties. Pharmaceuticals. 2020;13(11):343.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"5274_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.phytochem.2004.03.019","volume":"65","author":"MH Douglas","year":"2004","unstructured":"Douglas MH, van Klink JW, Smallfield BM, Perry NB, Anderson RE, Johnstone P, et al. Essential oils from new Zealand manuka: triketone and other chemotypes of leptospermum scoparium. Phytochemistry. 2004;65(9):1255\u201364.","journal-title":"Phytochemistry"},{"key":"5274_CR21","doi-asserted-by":"crossref","unstructured":"Shortt N, Martin A, Kerse K, Shortt G, Vakalalabure I, Barker L, et al. Efficacy of a 3% K\u0101nuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial. eClinicalMedicine. 2022;51:101561.","DOI":"10.1016\/j.eclinm.2022.101561"},{"issue":"1","key":"5274_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jmii.2013.12.009","volume":"49","author":"CC Chen","year":"2016","unstructured":"Chen CC, Yan SH, Yen MY, Wu PF, Liao WT, Huang TS, et al. Investigations of Kanuka and Manuka essential oils for in vitro treatment of disease and cellular inflammation caused by infectious microorganisms. J Microbiol Immunol Infect. 2016;49(1):104\u201311.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"5274_CR23","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.3892\/etm.2016.3850","volume":"12","author":"J Wang","year":"2016","unstructured":"Wang J, Su B, Zhu H, Chen C, Zhao G. Protective effect of geraniol inhibits inflammatory response, oxidative stress and apoptosis in traumatic injury of the spinal cord through modulation of NF-\u03baB and p38 MAPK. Exp Ther Med. 2016;12(6):3607\u201313.","journal-title":"Exp Ther Med"},{"issue":"5","key":"5274_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0031-9422(03)00226-7","volume":"63","author":"A Prashar","year":"2003","unstructured":"Prashar A, Hili P, Veness RG, Evans CS. Antimicrobial action of Palmarosa oil (Cymbopogon martinii) on Saccharomyces cerevisiae. Phytochemistry. 2003;63(5):569\u201375.","journal-title":"Phytochemistry"},{"key":"5274_CR25","doi-asserted-by":"crossref","unstructured":"Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-\u03b1 and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014 July;134(7):1941\u201350.","DOI":"10.1038\/jid.2014.83"},{"key":"5274_CR26","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.2147\/DDDT.S145702","volume":"12","author":"Y Huang","year":"2018","unstructured":"Huang Y, Yang XL, Ni YH, Xu ZM. Geraniol suppresses Proinflammatory mediators in phorbol 12-myristate 13-acetate with A23187-induced HMC-1 cells. Drug Des Devel Ther. 2018;12:2897\u2013903.","journal-title":"Drug Des Devel Ther"},{"key":"5274_CR27","doi-asserted-by":"crossref","unstructured":"M\u0105czka W, Wi\u0144ska K, Grabarczyk M. One Hundred Faces of Geraniol. Molecules. 2020 July 21;25(14).","DOI":"10.3390\/molecules25143303"},{"key":"5274_CR28","doi-asserted-by":"publisher","first-page":"104394","DOI":"10.1016\/j.fitote.2019.104394","volume":"139","author":"CJ Ye","year":"2019","unstructured":"Ye CJ, Li SA, Zhang Y, Lee WH. Geraniol targets KV1.3 ion channel and exhibits anti-inflammatory activity in vitro and in vivo. Fitoterapia. 2019;139:104394.","journal-title":"Fitoterapia"},{"issue":"6","key":"5274_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/BF02535593","volume":"23","author":"M Bard","year":"1988","unstructured":"Bard M, Albrecht MR, Gupta N, Guynn CJ, Stillwell W. Geraniol interferes with membrane functions in strains of Candida and Saccharomyces. Lipids. 1988;23(6):534\u20138.","journal-title":"Lipids"},{"issue":"6","key":"5274_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1055\/s-2000-8604","volume":"66","author":"F Christoph","year":"2000","unstructured":"Christoph F, Kaulfers PM, Stahl-Biskup E. A comparative study of the in vitro antimicrobial activity of tea tree oils s.l. With special reference to the activity of beta-triketones. Planta Med. 2000;66(6):556\u201360.","journal-title":"Planta Med"},{"issue":"24","key":"5274_CR31","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1016\/j.bmc.2005.07.045","volume":"13","author":"JW van Klink","year":"2005","unstructured":"van Klink JW, Larsen L, Perry NB, Weavers RT, Cook GM, Bremer PJ, et al. Triketones active against antibiotic-resistant bacteria: synthesis, structure-activity relationships, and mode of action. Bioorg Med Chem. 2005;13(24):6651\u201362.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"5274_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12906-024-04358-9","volume":"24","author":"G Shortt","year":"2024","unstructured":"Shortt G, Shortt N, Bird G, Kerse K, Lieffering N, Martin A, et al. M\u0101nuka oil based ECMT-154 versus vehicle control for the topical treatment of eczema: study protocol for a randomised controlled trial in community pharmacies in Aotearoa new Zealand. BMC Complement Med Ther. 2024;24(1):61.","journal-title":"BMC Complement Med Ther"},{"key":"5274_CR33","doi-asserted-by":"crossref","unstructured":"Spuls Pi G, Laa, Simpson E, Apfelbacher C j., Chalmers T Jr, Ks et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British J Dermatol. 2017;176(4):979\u201384.","DOI":"10.1111\/bjd.15179"},{"issue":"5","key":"5274_CR34","doi-asserted-by":"publisher","first-page":"e026201","DOI":"10.1136\/bmjopen-2018-026201","volume":"14","author":"A Semprini","year":"2019","unstructured":"Semprini A, Singer J, Braithwaite I, Shortt N, Thayabaran D, McConnell M, et al. Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial. BMJ Open. 2019;14(5):e026201.","journal-title":"BMJ Open"},{"issue":"8","key":"5274_CR35","doi-asserted-by":"publisher","first-page":"e017766","DOI":"10.1136\/bmjopen-2017-017766","volume":"7","author":"A Semprini","year":"2017","unstructured":"Semprini A, Singer J, Shortt N, Braithwaite I, Beasley R. Protocol for a randomised controlled trial of 90% Kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting. BMJ Open. 2017;7(8):e017766.","journal-title":"BMJ Open"},{"issue":"4","key":"5274_CR36","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","volume":"134","author":"J Schmitt","year":"2014","unstructured":"Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The harmonising outcome measures for eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"5274_CR37","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"5","key":"5274_CR38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/bjd.16367","volume":"178","author":"L Howells","year":"2018","unstructured":"Howells L, Ratib S, Chalmers JR, Bradshaw L, Thomas KS. CLOTHES trial team. How should minimally important change scores for the Patient-Oriented eczema measure be interpreted? A validation using varied methods. Br J Dermatol. 2018;178(5):1135\u201342.","journal-title":"Br J Dermatol"},{"issue":"8","key":"5274_CR39","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","volume":"66","author":"JF Stalder","year":"2011","unstructured":"Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114\u201321.","journal-title":"Allergy"},{"issue":"3","key":"5274_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"5274_CR41","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/bjd.15314","volume":"177","author":"FM Ali","year":"2017","unstructured":"Ali FM, Johns N, Finlay AY, Salek MS, Piguet V. Comparison of the paper-based and electronic versions of the dermatology life quality index: evidence of equivalence. Br J Dermatol. 2017;177(5):1306\u201315.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"5274_CR42","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","volume":"8","author":"MJ Atkinson","year":"2005","unstructured":"Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9\u201324.","journal-title":"Value Health"},{"issue":"1","key":"5274_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000245677","volume":"195","author":"B Kunz","year":"1997","unstructured":"Kunz B, Oranje AP, Labr\u00e8ze L, Stalder JF, Ring J, Ta\u00efeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European task force on atopic dermatitis. Dermatology. 1997;195(1):10\u20139.","journal-title":"Dermatology"},{"key":"5274_CR44","doi-asserted-by":"crossref","unstructured":"Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J, EASI, editors. (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99\u2013106.","DOI":"10.1111\/j.1398-9995.2011.02719.x"},{"issue":"2","key":"5274_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"5274_CR46","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019 July;95:103208.","DOI":"10.1016\/j.jbi.2019.103208"},{"issue":"1","key":"5274_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MKA Basra","year":"2015","unstructured":"Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"key":"5274_CR48","first-page":"CD012119","volume":"2","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BW. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:CD012119.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"5274_CR49","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the eczema area and severity index score tells Us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"5274_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/1757975914528961","volume":"22","author":"M Glover","year":"2015","unstructured":"Glover M, Kira A, Johnston V, Walker N, Thomas D, Chang AB, et al. A systematic review of barriers and facilitators to participation in randomized controlled trials by Indigenous people from new Zealand, Australia, Canada and the united States. Glob Health Promot. 2015;22(1):21\u201331.","journal-title":"Glob Health Promot"},{"issue":"2","key":"5274_CR51","first-page":"226","volume":"22","author":"GL Schmotzer","year":"2012","unstructured":"Schmotzer GL. Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis. 2012;22(2):226\u201330.","journal-title":"Ethn Dis"},{"key":"5274_CR52","unstructured":"Stats NZ. 2023 Census population counts (by ethnic group, age, and M\u0101ori descent) and dwelling counts [Internet]. 2024 May [cited 2025 Apr 4]. Available from: https:\/\/www.stats.govt.nz\/information-releases\/2023-census-population-counts-by-ethnic-group-age-and-maori-descent-and-dwelling-counts\/"},{"issue":"10","key":"5274_CR53","doi-asserted-by":"publisher","first-page":"e22810","DOI":"10.2196\/22810","volume":"22","author":"I Darmawan","year":"2020","unstructured":"Darmawan I, Bakker C, Brockman TA, Patten CA, Eder M. The role of social media in enhancing clinical trial recruitment: scoping review. J Med Internet Res. 2020;22(10):e22810.","journal-title":"J Med Internet Res"},{"issue":"12","key":"5274_CR54","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1017\/S136898002300246X","volume":"26","author":"MJ Henderson","year":"2023","unstructured":"Henderson MJ, Gow ML. A scoping review of health promotion interventions delivered via social media to women of reproductive age. Public Health Nutr. 2023;26(12):3173\u201389.","journal-title":"Public Health Nutr"},{"key":"5274_CR55","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.indcrop.2018.12.083","volume":"130","author":"SO Essien","year":"2019","unstructured":"Essien SO, Baroutian S, Dell K, Young B. Value-added potential of new Zealand m\u0101nuka and k\u0101nuka products: A review. Ind Crops Prod. 2019;130:198\u2013207.","journal-title":"Ind Crops Prod"},{"issue":"3","key":"5274_CR56","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0031-9422(98)00548-2","volume":"50","author":"NG Porter","year":"1999","unstructured":"Porter NG, Wilkins AL. Chemical, physical and antimicrobial properties of essential oils of Leptospermum scoparium and Kunzea Ericoides. Phytochemistry. 1999;50(3):407\u201315.","journal-title":"Phytochemistry"},{"key":"5274_CR57","unstructured":"Medicines Act. 1981 [Internet]. New Zealand Legislation; 2021 Dec [cited 2022 June 20]. Report No.: 118. Available from: https:\/\/www.legislation.govt.nz\/act\/public\/1981\/0118\/latest\/whole.html#DLM55429"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-026-05274-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:02:27Z","timestamp":1772625747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-026-05274-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5274"],"URL":"https:\/\/doi.org\/10.1186\/s12906-026-05274-w","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Central Health and Disability Ethics Committee (HDEC reference: 2021 EXP 11490). National Standing Committee on Therapeutic Trials (SCOTT ) approval was obtained (21\/SCOTT\/118), as required for all clinical trials investigating a new medicine under New Zealand legislation [\n                      \n                      ]. Electronic written informed consent to participate was obtained from all participants. Conduct of the study was in accordance with guidelines and regulations set forth by HDEC and SCOTT.Ethics approval was obtained from Central Health and Disability Ethics Committee on 3rd December 2021 (reference: 2021 EXP 11490. The Standing Committee on Therapeutic Trails (SCOTT) granted study approval on 20th September 2021 (reference: 21\/SCOTT\/118)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SH is the inventor of ECMT-154 (as described in International Publication Number WO2022\/234340 A1) and a shareholder of Manuka Bioscience. SH was also a contractor (R&D Strategist) at Manuka Bioscience. SH had input into protocol development but was not involved in study conduct or data analysis. AS and GS declare funding from Manuka Bioscience to the MRINZ for the submitted work. There are no other conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}